Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

Airbnb stock surged after fourth-quarter earnings beat expectations. It has largely missed out on the travel boom but that may be about to change as the short-term rental company positions its app to ...

Eco Wave Power has entered an MoU with Bharat Petroleum (BPCL) to harness India's wave energy potential, estimated at ...

The company provided 2025 guidance for TTR product sales of $1.6 billion to $1.725 billion, representing a 36% growth at the midpoint compared to 2024. This outlook assumes regulatory approval and the ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...

Hims is a US-based telehealth company offering online prescription medication, over-the-counter drugs, and personal care ...

As a leading provider of health-related education, with almost 6,500 students and approximately 250 academic staff, we offer an extensive portfolio of accredited degree and research programmes ...